Praluent Side Effects: Incidence Rates Across Clinical Trials

What the FDA Label Says About Alirocumab Adverse Events

The FDA-approved prescribing information for alirocumab lists adverse reactions observed at a rate of at least 2% and more frequently than placebo across placebo-controlled trials. Injection-site reactions, nasopharyngitis, and influenza are among the most consistently reported events. The label also carries a warning for serious hypersensitivity reactions, including hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization. [1]

Labeled Adverse Reactions by Frequency

According to the Praluent prescribing information, the following adverse reactions occurred in at least 2% of patients and more often than placebo across 14 placebo-controlled trials [1]:

• Nasopharyngitis: 11.3% alirocumab vs. 11.1% placebo
• Injection-site reactions: 7.2% vs. 5.1%
• Influenza: 5.7% vs. 4.8%
• Urinary tract infection: 4.8% vs. 4.3%
• Diarrhea: 4.7% vs. 4.3%
• Bronchitis: 4.3% vs. 3.8%
• Myalgia: 4.2% vs. 3.5%
• Muscle spasms: 3.0% vs. 2.5%
• Sinusitis: 3.5% vs. 3.1%
• Contusion: 2.3% vs. 1.5%
• Musculoskeletal pain: 2.2% vs. 1.8%

The label specifies that injection-site reactions include erythema, itching, swelling, and pain at the injection site. [1]

What the Label Does Not Capture

Post-approval pharmacovigilance extends beyond what a pre-market label can reflect. The FDA Adverse Event Reporting System (FAERS) database documents spontaneous reports from real-world use. FAERS entries for alirocumab include hypersensitivity reactions, angioedema, and rare cases of rhabdomyolysis, though causality in spontaneous reports is not established. Clinicians should review updated FAERS summaries for emerging signals, accessible through the FDA's MedWatch program. [2]

ODYSSEY Phase III Program: Trial-by-Trial Adverse Event Data

The ODYSSEY phase III program enrolled more than 23,500 patients across 14 trials. Each trial targeted a distinct population, allowing comparison of the safety profile across statin-intolerant patients, familial hypercholesterolemia populations, and general high-cardiovascular-risk groups. [3]

ODYSSEY LONG TERM (N=2,341)

ODYSSEY LONG TERM evaluated alirocumab 150 mg every 2 weeks in patients already on maximally tolerated statin therapy. At 78 weeks, adverse events leading to treatment discontinuation occurred in 7.2% of alirocumab patients versus 5.8% of placebo patients. Injection-site reactions were reported in 5.9% of alirocumab recipients versus 4.4% placebo. Neurocognitive events were reported in 1.2% alirocumab versus 0.5% placebo, though the absolute numbers were small and the mechanism was not established. [4]

A post-hoc analysis of patients who achieved LDL-C <25 mg/dL in ODYSSEY LONG TERM found no significant difference in adverse event rates compared with patients who maintained higher LDL-C concentrations. [4]

ODYSSEY ALTERNATIVE (N=361): Statin-Intolerant Patients

ODYSSEY ALTERNATIVE specifically enrolled patients with documented statin intolerance due to muscle-related adverse events. At 24 weeks, muscle-related adverse events occurred in 32.5% of alirocumab patients versus 46.0% receiving ezetimibe and 22.2% receiving placebo. The higher rate in alirocumab relative to placebo is thought to reflect nocebo effects and background myalgia in a statin-sensitized population. [5]

Skeletal muscle adverse events leading to permanent treatment discontinuation occurred in 7.2% alirocumab versus 29.1% ezetimibe, suggesting that for patients who cannot tolerate statins, alirocumab may carry a lower muscle-AE burden than the standard statin alternative. [5]

ODYSSEY FH I and FH II (N=735 combined)

These trials enrolled patients with heterozygous familial hypercholesterolemia. Across both trials, adverse events were reported at similar rates between alirocumab and placebo groups. Injection-site reactions occurred in 12.4% alirocumab versus 11.2% placebo in FH I, and 11.3% versus 7.8% in FH II. No serious injection-site reactions were reported. [6]

ODYSSEY CHOICE I (75 mg every 2 weeks, dose adjustment allowed)

ODYSSEY CHOICE I tested the 75 mg starting dose with potential uptitration to 150 mg. Among 803 patients over 52 weeks, any adverse event was reported in 72.4% alirocumab versus 74.4% placebo. Serious adverse events occurred in 9.6% vs. 11.2%. The similar or lower serious AE rate in the alirocumab arm was consistent across the broader ODYSSEY program. [7]

ODYSSEY OUTCOMES: The Cardiovascular Outcomes Trial

ODYSSEY OUTCOMES is the largest single source of alirocumab safety data, enrolling 18,924 patients with acute coronary syndrome and following them for a median of 2.8 years. [8]

Primary Safety Findings

The New England Journal of Medicine publication of ODYSSEY OUTCOMES reported that any adverse event led to discontinuation of the study drug in 5.3% of alirocumab patients versus 4.8% of placebo patients. Injection-site reactions occurred in 3.8% alirocumab versus 2.1% placebo (P<0.001). [8]

Neurocognitive events were reported in 1.2% alirocumab versus 1.1% placebo, a difference that was not statistically significant (P<0.84). This finding was notable given early signals of neurocognitive concern reported anecdotally during the initial post-marketing period. [8]

Diabetes mellitus new-onset occurred in 9.6% alirocumab versus 10.1% placebo, suggesting alirocumab does not increase diabetes risk. [8]

The Very-Low LDL-C Safety Question

A pre-specified analysis within ODYSSEY OUTCOMES examined 730 patients who sustained LDL-C levels <15 mg/dL. In this subgroup, no increase in adverse events including neurocognitive events, new-onset diabetes, or muscle-related events was detected compared with patients who maintained higher LDL-C. [9]

The ODYSSEY OUTCOMES investigators concluded: "Patients with very low achieved LDL-C levels did not have significantly higher rates of adverse events." [9] This addressed a theoretical concern that extremely suppressed LDL-C might impair neuronal membrane function or steroid hormone synthesis.

Hemorrhagic Stroke Signal

ODYSSEY OUTCOMES reported hemorrhagic stroke in 0.6% alirocumab patients versus 0.5% placebo. The difference was not statistically significant, and total stroke (including ischemic) favored alirocumab (1.9% vs. 2.4%, P=0.01). [8]

Injection-Site Reactions: Detailed Breakdown

Injection-site reactions are the most clinically discussed adverse event associated with alirocumab, appearing consistently across trials. They are generally mild and self-limiting.

Characterization and Timing

In pooled data from the ODYSSEY phase III program, injection-site reactions affected 7.2% of alirocumab patients versus 5.1% placebo. The reactions most often presented as erythema, pruritus, or mild swelling at the 1 mL subcutaneous injection site. Most resolved within 7 days without intervention. [1]

Serious injection-site reactions requiring medical attention were reported in fewer than 0.5% of alirocumab patients across phase III trials. Rotating injection sites and confirming proper injection technique reduced recurrence in post-market clinical practice. [10]

Comparison with Evolocumab

Evolocumab (Repatha), the other approved PCSK9 inhibitor, reported injection-site reactions in 2.1% of patients versus 1.6% placebo in the FOURIER trial (N=27,564). [11] The numerically higher injection-site reaction rate with alirocumab versus evolocumab may reflect differences in formulation and the 1 mL versus 1 mL injection volumes, though head-to-head comparative injection-site tolerability data are limited.

Allergic and Hypersensitivity Reactions

Across the ODYSSEY phase III program, allergic reactions including hypersensitivity were reported in 8.6% alirocumab patients versus 7.8% placebo. [1]

Serious Hypersensitivity Events

Serious hypersensitivity reactions, including hypersensitivity vasculitis and reactions requiring hospitalization, were reported in fewer than 1% of alirocumab-treated patients across clinical trials. The FDA prescribing information specifies that if signs or symptoms of serious allergic reactions occur, treatment should be discontinued and appropriate therapy initiated. [1]

Post-marketing reports to FAERS have included cases of angioedema. The reporting rate for angioedema in FAERS does not establish causality but triggered the addition of this information to post-market safety communications. [2]

Managing Hypersensitivity in Practice

Patients with a prior history of severe drug hypersensitivity should be observed for at least 30 minutes after the first injection when feasible. The monoclonal antibody structure of alirocumab means reactions are mediated through different immune pathways than small-molecule drug allergies. Rechallenge after a mild reaction may be possible with physician supervision, though rechallenge after anaphylaxis is contraindicated. [1]

Neurocognitive Adverse Events: Separating Signal from Noise

Early post-market reports suggested a possible association between PCSK9 inhibition and neurocognitive events, including confusion and memory impairment. The FDA issued a safety communication in 2017 requesting evaluation of this potential risk. [12]

FDA Communication and Trial Data

The FDA's 2017 Drug Safety Communication noted that post-marketing reports described confusion and memory impairment in patients taking PCSK9 inhibitors. [12] The FDA stated that these events were generally not serious and resolved after drug discontinuation in most cases.

Across the ODYSSEY phase III program, neurocognitive adverse events occurred in 0.8% alirocumab versus 0.7% placebo. [3] The ODYSSEY OUTCOMES trial, with its larger sample and longer follow-up, found rates of 1.2% versus 1.1%, with no statistically significant difference. [8]

Mechanistic Context

LDL-C and other lipoproteins contribute to neuronal membrane composition and myelin synthesis. The theoretical concern is that very deep LDL-C suppression could impair these processes. However, the FOURIER Cognitive Study (EBBINGHAUS, N=1,204) found no significant difference in neurocognitive function between evolocumab and placebo-treated patients using validated cognitive assessments over 19 months. [13] Alirocumab lacks an equivalent dedicated cognitive sub-study, but the ODYSSEY OUTCOMES neurocognitive data in the very-low LDL-C subgroup aligns with the EBBINGHAUS null finding.

Muscle-Related Adverse Events

Myalgia appeared in 4.2% alirocumab versus 3.5% placebo in the FDA-label pooled dataset. [1] Given that the background population is largely on statins, interpreting any muscle signal requires care.

Creatine Kinase Elevations

In ODYSSEY LONG TERM, creatine kinase (CK) elevations greater than 3 times the upper limit of normal occurred in 2.4% alirocumab versus 1.6% placebo. CK elevations greater than 10 times the upper limit of normal were rare and occurred at similar rates in both groups. [4]

Statin-Intolerant Subgroup

In ODYSSEY ALTERNATIVE, the statin-intolerant population reported muscle-related adverse events in 32.5% alirocumab versus 46.0% ezetimibe. Myalgia of any grade occurred in 25.7% alirocumab versus 23.2% placebo in that trial, suggesting a nocebo effect in patients pre-sensitized to expecting muscle symptoms. [5]

The distinction between pharmacologically caused myalgia and nocebo-driven symptom reporting is clinically relevant. Shared decision-making with patients who have prior statin myalgia should include this distinction. [5]

Special Populations: Safety Data by Subgroup

Elderly Patients (Age 65 and Older)

Post-hoc analyses of the ODYSSEY OUTCOMES trial found no statistically significant differences in overall adverse event rates between patients 65 or older and younger patients. Injection-site reactions occurred at similar rates. The prescribing information notes that no dose adjustment is required in elderly patients based on available pharmacokinetic and safety data. [1]

Patients with Renal Impairment

Alirocumab pharmacokinetics are not meaningfully altered in mild to moderate renal impairment. No dose adjustment is recommended. Safety data in severe renal impairment are limited, and the FDA label reflects this gap with a cautionary note. [1]

Pregnancy and Lactation

Alirocumab is not recommended during pregnancy. Animal studies showed no teratogenicity, but IgG antibodies are known to cross the placenta, and no adequate human pregnancy data exist. The prescribing information states that women of childbearing potential should use effective contraception during treatment. [1] No data are available on the presence of alirocumab in human breast milk.

Post-Market Safety: FAERS and Real-World Data

The FDA FAERS database provides ongoing pharmacovigilance beyond what controlled trials can capture. As of the most recent publicly available FAERS quarterly reports, alirocumab (Praluent) has accumulated thousands of adverse event reports since its 2015 approval. [2]

Key FAERS Signals

Disproportionality analyses of FAERS data have identified the following adverse events with reporting odds ratios suggesting a potential drug association (note: FAERS reports do not prove causality) [2]:

• Injection-site reactions (reporting odds ratio significantly elevated)
• Hypersensitivity reactions including urticaria
• Angioedema (rare)
• Myalgia in statin-background patients
• Neurocognitive complaints (low absolute reporting rate)

Alirocumab Biosimilar Considerations

No alirocumab biosimilars are currently FDA-approved as of the date of this article. The original biological product remains the only commercially available version in the United States. Post-market safety data therefore reflect exclusively the reference product. [1]

Clinical Decision Framework: Matching Patient Profiles to Risk

The adverse event data across ODYSSEY trials support a tiered approach to patient selection and monitoring. Patients with a history of statin myalgia tolerate alirocumab at lower muscle-event rates than ezetimibe, per ODYSSEY ALTERNATIVE. Patients who achieved very low LDL-C in ODYSSEY OUTCOMES did not show elevated AE rates compared with the broader treated group.

The following framework synthesizes trial data into actionable prescribing guidance:

Tier 1 (routine monitoring): Patients starting alirocumab 75 mg every 2 weeks with no prior drug hypersensitivity or statin intolerance. Reassess LDL-C at 4-8 weeks. Watch for injection-site reactions during the first 3 months.

Tier 2 (enhanced monitoring): Patients with prior statin myalgia, atopy, or known drug hypersensitivity. Obtain baseline CK and liver function tests. Document injection-site reaction characteristics at each follow-up visit.

Tier 3 (specialist co-management): Patients with heterozygous familial hypercholesterolemia requiring LDL-C <55 mg/dL per ESC/EAS 2019 guidelines [14], or patients with LDL-C <25 mg/dL on 150 mg every 2 weeks. Review FAERS updates biannually for new signals.

Periodic LDL-C monitoring may guide dose reduction if LDL-C drops below 25 mg/dL on two consecutive measurements, consistent with label guidance to consider dose adjustment. [1]

Comparing Alirocumab and Evolocumab Safety Profiles

Both approved PCSK9 inhibitors share similar mechanisms and adverse event categories. Direct comparisons require reading across separate trials rather than head-to-head data.

In FOURIER (evolocumab, N=27,564, median 2.2 years), any adverse event occurred in 77.4% evolocumab versus 77.4% placebo. Injection-site reactions were 2.1% versus 1.6%. Neurocognitive events were not significantly different. [11]

In ODYSSEY OUTCOMES (alirocumab, N=18,924, median 2.8 years), discontinuation due to adverse events was 5.3% versus 4.8%. Injection-site reactions were 3.8% versus 2.1%. [8]

The numerically higher injection-site reaction rate in ODYSSEY OUTCOMES versus FOURIER likely reflects both biological product differences and differences in trial populations rather than a definitively superior tolerability profile for either agent. Neither trial was powered for direct between-drug comparisons. [8],[11]

Alirocumab Adverse Events in the Context of Statin Background Therapy

Most patients in ODYSSEY trials were receiving maximally tolerated statin therapy concurrently. Disentangling alirocumab-specific adverse events from statin-related effects is a persistent methodological challenge. [3]

A 2019 meta-analysis published in the European Heart Journal examining pooled PCSK9 inhibitor data (N=67,240 patients across 34 trials) found that PCSK9 inhibitors did not significantly increase the risk of any muscle-related adverse event compared with placebo (relative risk 0.99, 95% CI 0.96-1.03, P=0.68). [15]

The same meta-analysis reported that PCSK9 inhibitors were associated with a statistically significant increase in injection-site reactions (relative risk 1.53, 95% CI 1.28-1.84) but not with diabetes, neurocognitive events, or hepatic adverse events. [15]